Seegene Arab League
상단으로
اتصل بنا

أخبار المنتج يمكنك التحقق من أحدث معلومات المنتج

  • Chlamydia product received COC by EU NB

    Seeplex® CT ACE Detection Seeplex® CMV ACE Detection Chlamydia product received COC (Certificate of conformity) by EU NB (Notified Body). ITC (Institute for Testing and Certification).

    Jul 15, 2008｜ Seeplex® CT ACE Detection , Seeplex® CMV ACE Detection

  • Seeplex® STD6 ACE Detection: CE-IVD Marking

    Seeplex® STD6 ACE Detection Simultaneously detecting 6 different STD pathogens Seeplex® STD ACE Detection series are designed to simultaneously detect 6 sexually transmitted disease (STD) pathogens Seeplex® STD6 ACE Detection is designed to simultaneously detect 6 sexually transmitted disease(STD) pathogens from patients' samples (urine, urethral swab, vaginal swab, genital lesion swab, cervical brush/swab or liquid-based cytology specimen (ex. ThinPrep®, specimen transport medium, etc.)). The conventional methods (ELISA, Giemsa stain, culture, etc.) to detect STD pathogens take several days or suffer from poor sensitivity. Therefore, many of the recently developed diagnostic methods employ PCR methods. Among them, Seegene's STD Detection is outstanding in terms of sensitivity and specificity using a novel DPO™ technology and currently detects multiple pathogens causing sexually transmitted infections by Mutiplex PCR

    Jul 01, 2008｜ Seeplex® STD6 ACE Detection

  • Launched Seeplex® Sepsis DNA Test / Introduced at AACC

    Seeplex® Sepsis Screening SetScreening for sepsis-causing pathogensSeeplex® Sepsis Group Screening Set can screen for sepsis-causing pathogenes from periodontal and caries joint fluid, cerebrospinal fluid, blood cultures, urine, sputum, and other body fluids. * Launched Seeplex® Sepsis DNA Test * Introduced at the 2008 Annual   Meeting and Clinical Lab Expo of the American Association for Clinical Chemistry (AACC) The conventional method for sepsis diagnostics is blood culture. However, it takes up to several days for the result. Therefore it is not appropriate for a patient in an intensive care unit. Seeplex® Sepsis Group Screeing Set enables simultaneous screening for gram-negative and -positive bacteria and fungi that cause sepsis with multiplex PCR and provides more rapid results than culture testing.

    Jul 01, 2008｜ Seeplex® Sepsis DNA Test

  • Obtained CE-IVD marking for Seeplex® RV12 ACE Detection

    Simultaneous detection of 12 major respiratory viruses Seegene's Seeplex® RV12 ACE Detection, RV5 ACE Screening have been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.

    Jun 30, 2008｜ Seeplex® RV12 ACE Detection

  • Obtained CE-IVD marking for Seeplex® PneumoBacter ACE Detection

    Accurately detecting 6 pneumonial bacteria at once Seegene's Seeplex® PneumoBacter ACE Detection have been notified at Germany CA (Competent Authorities). The CE mark will allow more opportunities for Seegene to market and sell within the European Union.

    Jun 30, 2008｜ Seeplex® PneumoBacter ACE Detection

  • Seeplex® RV12 ACE Detection: CE-IVD Marking

    Seeplex® RV12 ACE DetectionSimultaneously detecting 12 major respiratory virusesSeeplex® RV 12 ACE Detection is designed to detect major respiratory viruses. The conventional methods (culture and IFA, etc.) to detect respiratory viruses take several days or do not have enough sensitivity. Therefore, many of the recently developed diagnostic methods employ PCR methods. Among them, Seegene's Respiratory Virus Detection is outstanding in terms of sensitivity and specificity by applying DPO™ technology and detects multiple respiratory viruses by Multiplex RT-PCR.

    Jun 03, 2008｜ Seeplex® RV12 ACE Detection

  • Seeplex® BRAF ACE Detection: CE-IVD Marking

    Seeplex® BRAF ACE DetectionBRAF mutation (V600E) DetectionSeeplex® BRAF V600E ACE Detection is designed to detect BRAF mutation (V600E) characteristic for papillary thyroid carcinoma. The BRAF gene involves in mediating cellular response to growth, differentiation and death signals in RAS RAF MEK MAP kinase pathway. BRAF mutations are common in melanoma, colon cancer, gliomas, and lung cancer. In 80% cases, it is a single substitution1),2) (V600E). Especially, in papillary thyroid carcinoma (PTC), the incidence of BRAF mutation occurs 26-69% (likely 45-50%) of all cases1),3). Seeplex® BRAF V600E ACE Detection tests BRAF mutation, the most common genetic mutation in PTC, with single PCR reaction by utilizing DPO™ technology.

    Jun 02, 2008｜ Seeplex® BRAF ACE Detection

  • Seeplex® RV/PB18 ASE Detection: CE-IVD Marking

    Seeplex® RV/PB18 ASE DetectionDetecting Major Respiratory PathogensSeeplex® RV/PB18 ASE Detection is designed to detect simultaneously 13 respiratory viruses and 5 pneumonia bacteria. Existing diagnostic methods have tested for some viruses and some bacteria. However, it is difficult to accurately diagnose co-infection of viruses and bacteria because until now there has been no method to detect two types using one test, and thus the proper prescription cannot be made at the appropriate time. Seegene's products make it possible to prescribe quickly in the early stage of symptoms with just one test by determining whether a respiratory infection has been caused by viruses or bacteria or both. If the influenza A or influenza B virus is detected using Seegene products, Oseltamivir or Zanamavir can be prescribed. If the respiratory syncytial virus is detected using Seegene products, Ribavirin can be prescribed. This product will help with the development of specific antiviral preparations and antibiotics in the long term, and ultimately make customized prescriptions possible. Capillary-based auto sequencers including ABI 3130/3100 are applicable for Seeplex® RV/PB18 ASE Detection.

    Jun 01, 2008｜ Seeplex® RV/PB18 ASE Detection

1112131415